Management of severe acute exacerbations of COPD: an updated narrative review

dc.contributor.author
Crisafulli, Ernesto
dc.contributor.author
Barbeta, Enric
dc.contributor.author
Ielpo, Antonella
dc.contributor.author
Torres Martí, Antoni
dc.date.issued
2019-05-20T14:31:06Z
dc.date.issued
2019-05-20T14:31:06Z
dc.date.issued
2018-10-02
dc.date.issued
2019-05-20T14:31:06Z
dc.identifier
1828-695X
dc.identifier
https://hdl.handle.net/2445/133480
dc.identifier
686793
dc.identifier
30302247
dc.description.abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) may experience an acute worsening of respiratory symptoms that results in additional therapy; this event is defined as a COPD exacerbation (AECOPD). Hospitalization for AECOPD is accompanied by a rapid decline in health status with a high risk of mortality or other negative outcomes such as need for endotracheal intubation or intensive care unit (ICU) admission. Treatments for AECOPD aim to minimize the negative impact of the current exacerbation and to prevent subsequent events, such as relapse or readmission to hospital. Main body: In this narrative review, we update the scientific evidence about the in-hospital pharmacological and non-pharmacological treatments used in the management of a severe AECOPD. We review inhaled bronchodilators, steroids, and antibiotics for the pharmacological approach, and oxygen, high flow nasal cannulae (HFNC) oxygen therapy, non-invasive mechanical ventilation (NIMV) and pulmonary rehabilitation (PR) as non-pharmacological treatments. We also review some studies of non-conventional drugs that have been proposed for severe AECOPD. Conclusion: Several treatments exist for severe AECOPD patients requiring hospitalization. Some treatments such as steroids and NIMV (in patients admitted with a hypercapnic acute respiratory failure and respiratory acidosis) are supported by strong evidence of their efficacy. HFNC oxygen therapy needs further prospective studies. Although antibiotics are preferred in ICU patients, there is a lack of evidence regarding the preferred drugs and optimal duration of treatment for non-ICU patients. Early rehabilitation, if associated with standard treatment of patients, is recommended due to its feasibility and safety. There are currently few promising new drugs or new applications of existing drugs.
dc.format
15 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
BioMed Central
dc.relation
Reproducció del document publicat a: https://doi.org/10.1186/s40248-018-0149-0
dc.relation
Multidisciplinary Respiratory Medicine, 2018, vol. 13, num. 36
dc.relation
https://doi.org/10.1186/s40248-018-0149-0
dc.rights
cc-by (c) Crisafulli, Ernesto et al., 2018
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Malalties pulmonars obstructives cròniques
dc.subject
Antibiòtics
dc.subject
Oxigen
dc.subject
Respiració artificial
dc.subject
Chronic obstructive pulmonary diseases
dc.subject
Antibiotics
dc.subject
Oxygen
dc.subject
Artificial respiration
dc.title
Management of severe acute exacerbations of COPD: an updated narrative review
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.